Redeye: Transtema - Set for Exciting 2023
Redeye retains its positive view of Transtema and foresees a strong 2023 fueled by organic and acquired sales growth combined with a slight margin improvement. Recent acquisitions reduce the group’s customer concentration and strengthen its offerings in several growth areas.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking.